Controlled Release of Doxorubicin for Targeted Chemo-Photothermal Therapy in Breast Cancer HS578T Cells Using Albumin Modified Hybrid Nanocarriers

• Published in: International journal of molecular sciences Vol. 22; no. 20; p. 11228
• Main Authors: Carrese, Barbara, Cavallini, Chiara, Sanità, Gennaro, Armanetti, Paolo, Silvestri, Brigida, Calì, Gaetano, Pota, Giulio, Luciani, Giuseppina, Menichetti, Luca, Lamberti, Annalisa
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 18-10-2021; MDPI
• Subjects: Albumins; Albumins - chemistry; Antibiotics, Antineoplastic - pharmacology; Apoptosis; Binding sites; Breast cancer; Breast Neoplasms - metabolism; Breast Neoplasms - pathology; Breast Neoplasms - therapy; Cancer therapies; Cell cycle; Cell Proliferation; Chemotherapy; Combined Modality Therapy; Controlled release; Cytotoxicity; Doxorubicin; Doxorubicin - pharmacology; Drug Carriers - chemistry; Drug delivery; Drug Delivery Systems; Drug Liberation; Drugs; Efficiency; Female; Humans; hybrid nanoparticles; Infrared Rays; Melanin; melanin nanoparticles; Microscopy; Nanomaterials; Nanoparticles; Nanoparticles - administration & dosage; Nanoparticles - chemistry; Nanotechnology; photothermal; Photothermal Therapy - methods; Proteins; PTT; Silver; Toxicity; Tumor Cells, Cultured; PTT; melanin nanoparticles; hybrid nanoparticles; photothermal; breast cancer; doxorubicin; drug delivery
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms222011228

Hybrid nanomaterials have attracted research interest owing to their intriguing properties, which may offer new diagnostic options with triggering features, able to realize a new kind of tunable nanotherapeutics. Hybrid silica/melanin nanoparticles (NPs) containing silver seeds (Me-laSil_Ag-HSA NPs) disclosed relevant photoacoustic contrast for molecular imaging. In this study we explored therapeutic function in the same nanoplatform. For this purpose, MelaSil_Ag-HSA were loaded with doxorubicin (DOX) (MelaSil_Ag-HSA@DOX) and tested to assess the efficiency of drug delivery combined with concurrent photothermal treatment. The excellent photothermal properties allowed enhanced cytotoxic activity at significantly lower doses than neat chemotherapeutic treatment. The results revealed that MelaSil_Ag-HSA@DOX is a promising platform for an integrated photothermal (PT) chemotherapy approach, reducing the efficacy concentration of the DOX and, thus, potentially limiting the several adverse side effects of the drug in in vivo treatments.